Currently targeted therapy is one of the major methods of medical treatment for cancer. The creation of new radiopharmaceuticals to treat and diagnose neuroendocrine tumors expressing somatostatin receptors is a topical task that is needed to increase their selectiveness and to overcome tumor resistance that occurs. The search for new vectors and more efficient conjugates is required for this goal. A new method of conjugate synthesis based on pentapeptides (somatostatin analogs) containing the aryl-substituted thiazolidinecarboxylic acids was developed. The most optimal ethylenediamine is proposed as a linker, binding the vector with the chelator.
Buy this Article